Miyu Morohashi

Introduction Click to copy section linkSection link copied! Multidrug-resistant (MDR) bacteria have emerged as a major global health threat that severely limits the effectiveness of existing antibiotics. (1−3) Cyclic lipopeptides, such as colistin, serve as last-resort agents against MDR Gram-negative pathogens; however, the rapid rise of colistin-resistant strains has highlighted the urgent need for new therapeutic strategies.